The Future of Medicine is Data

OwkinAt the 2023 Annual J.P. Morgan Healthcare Conference, Owkin Co-founder and CEO Thomas Clozel, MD will outline how data is the future of medicine - from the development of new drugs to patient treatment decisions.

At 3pm (PST) on Tuesday the 10th of January at the Golden Gate Hotel, San Francisco, Thomas will discuss how finding the right treatment for every patient can only be achieved by the secure analysis of high-quality data, with data flowing freely yet securely between care and research. He will argue that allowing access to multimodal, KOL-selected and longitudinal patient data at scale and breaking research and competitive silos - while safeguarding security and privacy - are crucial to achieving precision medicine.

He will also highlight two technologies that Owkin is pioneering: firstly, using federated learning in clinical settings to create robust and global AI datasets, and secondly, using AI to gain a multiscale understanding of cause and effect in cancer biology, allowing researchers to predict how molecular perturbations impact cells, the tumor microenvironment and a patient’s outcome.

Thomas will outline how Owkin is delivering this vision by sharing Owkin’s recent successes in enhancing both biopharmaceutical research and care through unprecedented academic and industry collaborations, landmark strategic drug discovery and development partnerships, and the launch of world-first AI diagnostic solutions.

At last year's conference, Thomas outlined the limits of the historic applications of AI in drug discovery, arguing instead that AI should be used as an interactive tool that biologists, developers and physicians can use to co-create new knowledge.

Attending the conference alongside Thomas will be Alban de La Sablière, Chief Business Officer, Anna Huyghues-Despointes, Chief Corporate Development Officer, Jean-Frédéric Petit-Nivard, Chief Commercial Officer, and Joseph Lehár, SVP R&D Strategy.

Learn more about the 41st Annual J.P. Morgan Healthcare Conference, held in San Francisco from the 9th to the 12th of January.

About Thomas Clozel MD

Thomas Clozel MD is Co-founder and CEO of Owkin, leading medical research and business intelligence. He is a former Assistant Professor of Clinical Onco-Hematology at Hopital Henri Mondor in Paris and a former member of Ari Melnick's lab at the Weill Cornell Medical College, where he co-led several projects focused on prediction of resistance to chemotherapy in B-cell lymphoma. He co-founded Owkin with Gilles Wainrib in 2016.

About Owkin

Owkin is an AI biotechnology company that uses AI to find the right treatment for every patient. We combine the best of human and artificial intelligence to answer the research questions shared by biopharma and academic researchers. By closing the translational gap between complex biology and new treatments, we bring new diagnostics and drugs to patients sooner.

We use AI to identify new treatments, de-risk and accelerate clinical trials and build diagnostic tools. Using federated learning, a pioneering collaborative AI framework, Owkin enables partners to unlock valuable insights from siloed datasets while protecting patient privacy and securing proprietary data.

Owkin was co-founded by Thomas Clozel MD, a former assistant professor in clinical onco-hematology, and Gilles Wainrib, a pioneer in the field of machine learning in biology, in 2016. Owkin has raised over $300 million and became a unicorn through investments from leading biopharma companies (Sanofi and BMS) and venture funds (Fidelity, GV and BPI, among others).

Most Popular Now

AI also Assesses Dutch Mammograms Better…

AI is detecting tumors more often and earlier in the Dutch breast cancer screening program. Those tumors can then be treated at an earlier stage. This has been demonstrated by...

RSNA AI Challenge Models can Independent…

Algorithms submitted for an AI Challenge hosted by the Radiological Society of North America (RSNA) have shown excellent performance for detecting breast cancers on mammography images, increasing screening sensitivity while...

Unlocking the 10 Year Health Plan

The government's plan for the NHS is a huge document. Jane Stephenson, chief executive of SPARK TSL, argues the key to unlocking its digital ambitions is to consider what it...

AI can Find Cancer Pathologists Miss

Men assessed as healthy after a pathologist analyses their tissue sample may still have an early form of prostate cancer. Using AI, researchers at Uppsala University have been able to...

Alcidion Grows Top Talent in the UK, wit…

Alcidion has today announced the addition of three new appointments to their UK-based team, with one internal promotion and two external recruits. Dr Paul Deffley has been announced as the...

How AI could Speed the Development of RN…

Using artificial intelligence (AI), MIT researchers have come up with a new way to design nanoparticles that can more efficiently deliver RNA vaccines and other types of RNA therapies. After training...

AI, Full Automation could Expand Artific…

Automated insulin delivery (AID) systems such as the UVA Health-developed artificial pancreas could help more type 1 diabetes patients if the devices become fully automated, according to a new review...

MIT Researchers Use Generative AI to Des…

With help from artificial intelligence, MIT researchers have designed novel antibiotics that can combat two hard-to-treat infections: drug-resistant Neisseria gonorrhoeae and multi-drug-resistant Staphylococcus aureus (MRSA). Using generative AI algorithms, the research...

Penn Developed AI Tools and Datasets Hel…

Doctors treating kidney disease have long depended on trial-and-error to find the best therapies for individual patients. Now, new artificial intelligence (AI) tools developed by researchers in the Perelman School...

AI Hybrid Strategy Improves Mammogram In…

A hybrid reading strategy for screening mammography, developed by Dutch researchers and deployed retrospectively to more than 40,000 exams, reduced radiologist workload by 38% without changing recall or cancer detection...

New Training Year Starts at Siemens Heal…

In September, 197 school graduates will start their vocational training or dual studies in Germany at Siemens Healthineers. 117 apprentices and 80 dual students will begin their careers at Siemens...

Routine AI Assistance may Lead to Loss o…

The introduction of artificial intelligence (AI) to assist colonoscopies is linked to a reduction in the ability of endoscopists (health professionals who perform colonoscopies) to detect precancerous growths (adenomas) in...